In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation.
BACKGROUND
We previously identified in piglet cardiac allografts an immunoinflammatory response in coronary arteries in which increased fibronectin regulated by interleukin-1 beta was associated with early evidence of intimal thickening. In the present study, we used rabbits to assess whether acute neointimal formation after cardiac transplantation was reduced by blockade of tumor necrosis factor (TNF)-alpha, which modulates interleukin-1 beta, or by cyclosporine A.


RESULTS
Sixteen rabbits underwent heterotopic cardiac transplantation and were given saline, TNF-soluble receptor (sr), or cyclosporine A. In host hearts from saline- or TNFsr-treated groups, few coronary arteries (approximately 13% to 16%) had intimal thickening, whereas values were higher in the cyclosporine A-treated group (approximately 30%). In donor hearts from the saline-treated group, however, approximately 68% of vessels had intimal thickening versus approximately 32% in TNFsr- and approximately 30% in cyclosporine A-treated groups (P < .01 for both). Severity of intimal thickening assessed quantitatively as percent vessel area was approximately 38% in the saline-treated group but reduced in TNFsr- and cyclosporine A-treated groups to approximately 22% and 18%, respectively (P < .01 for each). Immunohistochemistry revealed increased staining for major histocompatibility complex II, T cells, interleukin-1 beta, TNF-alpha, and fibronectin in donor coronary arteries from saline-treated animals when compared with TNFsr- and cyclosporine A-treated animals. Grade 3 myocardial rejection was observed in both saline- and TNFsr-treated groups, but only grade 1 was apparent in the cyclosporine A-treated group.


CONCLUSIONS
In vivo blockade of TNF-alpha suppresses the acute development of neointimal formation by selectively reducing the vascular immunoinflammatory reaction and accumulation of fibronectin, whereas cyclosporine A suppresses both the myocardial and the vascular immune reaction.
Clausell
N
N
Division of Cardiovascular Research, Hospital for Sick Children, Toronto, Ontario, Canada.
Molossi
S
S
Sett
S
S
Rabinovitch
M
M
D000208:Acute Disease; D000818:Animals; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003327:Coronary Disease / Q000517:prevention & control; D003331:Coronary Vessels / Q000276:immunology / Q000473:pathology*; D005260:Female; D005353:Fibronectins / Q000032:analysis; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects*; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D007375:Interleukin-1 / Q000032:analysis; D009131:Muscle, Smooth, Vascular / Q000473:pathology*; D011817:Rabbits; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000502:physiology
D002791:Cholesterol, Dietary; D005353:Fibronectins; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha